{"filing":{"accession_number":"0001193125-26-278068","cik":"0001544227","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d158247d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526278068/d158247d8k.htm"},"events":[{"id":12942,"run_id":11482,"accession_number":"0001193125-26-278068","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 discloses the final results of a Special Meeting of Stockholders held on June 18, 2026, where stockholders voted on two proposals to approve issuances of common stock pursuant to Nasdaq Rule 5635 — specifically approving up to 925,927 shares from Series A and B Warrants (Proposal 1) and 2,344,828 shares from Common Warrants (Proposal 2). Both proposals passed with overwhelming majorities. The disclosure of shareholder vote results at a stockholder meeting is the core purpose of Item 5.07, and approval of dilutive warrant exercises is material to investors assessing capital structure and ownership dilution.","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9936,"accession_number":"0001193125-26-278068","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the final results of a Special Meeting of Stockholders held on June 18, 2026, where stockholders voted on two proposals to approve issuances of common stock pursuant to Nasdaq Rule 5635 — specifically approving up to 925,927 shares from Series A and B Warrants (Proposal 1) and 2,344,828 shares from Common Warrants (Proposal 2). Both proposals passed with overwhelming majorities. The disclosure of shareholder vote results at a stockholder meeting is the core purpose of Item 5.07, and approval of dilutive warrant exercises is material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T10:06:08.977167+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9936,"accession_number":"0001193125-26-278068","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the final results of a Special Meeting of Stockholders held on June 18, 2026, where stockholders voted on two proposals to approve issuances of common stock pursuant to Nasdaq Rule 5635 — specifically approving up to 925,927 shares from Series A and B Warrants (Proposal 1) and 2,344,828 shares from Common Warrants (Proposal 2). Both proposals passed with overwhelming majorities. The disclosure of shareholder vote results at a stockholder meeting is the core purpose of Item 5.07, and approval of dilutive warrant exercises is material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T10:06:08.977167+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-06-22"}]}